Brind.
  1. AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.

The competitive landscape heats up as Sanofi's Dupixent faces challenges from AbbVie's new drug and Zumilokibart.

1 report, 1 independent Updated Jun 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The competitive landscape heats up as Sanofi's Dupixent faces challenges from AbbVie's new drug and Zumilokibart.

Who's involved

What this event is mainly about
AbbVieSanofi

Keep exploring

Part of

AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share. All 3 developments

The entities involved

Coverage

Newest first; wire copies grouped